Provided by Tiger Trade Technology Pte. Ltd.

Bicycle Therapeutics Limited

4.78
-0.2600-5.16%
Post-market: 4.790.0100+0.21%19:33 EDT
Volume:418.82K
Turnover:2.03M
Market Cap:331.58M
PE:-1.32
High:5.10
Open:5.06
Low:4.77
Close:5.04
52wk High:10.32
52wk Low:4.77
Shares:69.37M
Float Shares:3.08M
Volume Ratio:1.07
T/O Rate:13.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6211
EPS(LYR):-2.9039
ROE:-34.59%
ROA:-20.59%
PB:0.54
PE(LYR):-1.65

Loading ...

European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading

MT Newswires Live
·
Nov 25, 2025

Bicycle Therapeutics initiated with a Hold at Truist

TIPRANKS
·
Nov 24, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week

MT Newswires Live
·
Nov 22, 2025

European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading

MT Newswires Live
·
Nov 18, 2025

Bicycle Therapeutics Joins Jefferies London Healthcare Conference

Reuters
·
Nov 13, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Nov 07, 2025

European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading

MT Newswires Live
·
Nov 04, 2025

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Bicycle Therapeutics (BCYC)

TIPRANKS
·
Oct 31, 2025

Stock Track | Bicycle Therapeutics Plunges 6% Following RBC Downgrade and Target Price Cut

Stock Track
·
Oct 31, 2025

Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)

TIPRANKS
·
Oct 31, 2025

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

TIPRANKS
·
Oct 31, 2025

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Bicycle Therapeutics (BCYC) and Foghorn Therapeutics (FHTX)

TIPRANKS
·
Oct 31, 2025

TD Cowen Remains a Buy on Bicycle Therapeutics (BCYC)

TIPRANKS
·
Oct 30, 2025

Bicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Oct 30, 2025

Bicycle Therapeutics Unveils Investor Presentation Highlighting Precision Oncology Platform and Pipeline Advances

Reuters
·
Oct 30, 2025

Bicycle Therapeutics Q3 net loss widens as R&D costs rise

Reuters
·
Oct 30, 2025

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

THOMSON REUTERS
·
Oct 30, 2025

Bicycle Therapeutics Plc - Cash and Cash Equivalents of $648.3 Mln as of Sept 30, 2025

THOMSON REUTERS
·
Oct 30, 2025

Bicycle Therapeutics Plc - Dose Selection From Phase 2/3 Duravelo-2 Trial and Update on Potential Approval Pathway Expected in 1Q 2026

THOMSON REUTERS
·
Oct 30, 2025

Bicycle Therapeutics Q3 Pretax Profit USD -58.895 Million

THOMSON REUTERS
·
Oct 30, 2025